Case-control study examines therapy response in IBD patients with primary sclerosing cholangitis, highlighting challenges of nonresponse.
Introduction: Biological therapies have improved outcomes of patients diagnosed with Inflammatory Bowel Diseases (IBD) such as Ulcerative colitis (UC) and Crohn's disease (CD). However, nonresponse or loss of response remains a significant challenge. Primary sclerosing cholangitis (PSC) is associated with IBDs, but the impact of concurrent PSC on response to IBD therapy is not well explored.
No takes yet. Share an insight, caveat, or question.
Tosse et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: